Compass Therapeutics Inc. (CMPX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.90 (+2.70%), Market cap $0.34B, 52-week low–high $1.67 ~ $6.69.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a
Financial statements, price targets, institutional (13F) holdings and related news for Compass Therapeutics Inc. are updated in real time on BlackAll Trade.
Compass Therapeutics Inc. trades at $1.90 (+2.70%). Real-time quotes and charts are available on BlackAll Trade.
Compass Therapeutics Inc. has a market cap of about $0.34B.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The comp